In the dark: Johnson & Johnson’s Animas
Johnson & Johnson’s Animas subsidiary seemed ahead of the curve in 2013 when it was testing its 1st-gen closed loop insulin delivery system, but the company hasn’t updated on the status of the device since then.
The company was reportedly developing an Animas pump with built-in hypoglycemia-hyperglycemia minimizer algorithm, and seemed to be ahead of competitor Medtronic in the early stages of development, producing 2 feasibility studies of the device.
But Animas has gone silent on the project. Earlier this year, Johnson & Johnson was said to be considering “strategic options” for its diabetes businesses, including LifeScan, Calibra Medical and Animas brands.
“Strategic options may include the formation of operating partnerships, joint ventures or strategic alliances, a sale of the businesses, or other alternatives either separately or together,” the healthcare conglomerate said in reporting its 4th-quarter and full-year earnings in late January. “All options will be evaluated to determine the best opportunity to drive future growth and maximize shareholder value. There can be no assurance that this process will result in any transaction or other strategic alternative of any kind.”
Diabetes sales were off for both periods, sliding -3.8% to $462 million during Q4 and -7.2% to $1.79 billion for full-year 2016.
Gayle Kirma says
I’m patiently waiting for this to hit the marke; T1 for 58 years!
Thank you!
Chris Newmarker says
Thanks for the comment, Gayle. Hope you don’t have to wait much longer!
James Dunlop says
but what about the advancements in this? worth looking at, it is being investigated by the same people that are investing in this product. hope for us T1 diabetics is coming, one way or another. there is hope.
http://thejdca.org/practical-cure-project-update-bcg
Erika Payne says
Hats off to you, Gayle.
Waiting impatiently.
Mum of a 10-year-old T1
Debbie says
How do i get to be in the trial?
Ronnie McBride says
This will be great. I am 67 years old and am fighting the battle of diabetes. I would love to trial test something like this. I worked in the Medical field for 39 years and was always studying how to beat this terrible disease.
Ronnie McBride
James Culp says
I wish all success. I hope for biological approach to protect islet insulin producing cells for implant or infusion of cells to restore natural function of glucose metabolism. May God help us.
Pat McAlister says
T1D for 70 years. Why not a cure instead of costing us more and more to live. We are the support of these drug and device companies. Thank you for this article. I do a diabetic newsletter for a T1D optimist club. Our next speaker is building his own device.
Chris Newmarker says
Thanks for the insights, Pat. I think it really says something about the motivation of the diabetes community that there’s so much do-it-yourself activity going on with devices, including when it comes to an artificial pancreas. Who do you have speaking?
Frank van Olffen says
You forgetting a big player in the Netherlands.
https://inredadiabetic.nl
Chris Newmarker says
Thanks for pointing out, Frank!